Autoimmune bullous skin diseases, such as pemphigus vulgaris (PV) and bullous pemphigoid (BP), are severe, frequently life-threatening skin disorders. Immunologically, they are characterized by the presence of serum autoantibodies (auto-Ab) targeting distinct adhesion molecules of the epidermis or dermoepidermal basement membrane zone. Antibody (Ab) binding interferes with the adhesive function of these molecules, leading to detachment and subsequently blister formation. PV is the classical example of an Ab-mediated autoimmune disease affecting epidermal adhesion. Auto-Ab against the desmosomal adhesion molecule, desmoglein 3 (Dsg3), are critical in the pathogenesis of this disease, since the transfer of serum IgG Ab reactive with Dsg3 into newborn mice induces a bullous skin disease resembling PV. Autoreactive T cell responses to Dsg3 may be critical in the pathogenesis of PV because: (1) Ab production generally requires T cell help; (2) the involvement of CD4+ T lymphocytes in PV has been suggested by the strong association with distinct HLA class II alleles, and (3) T cell recognition of epitopes of Dsg3 may be crucial for the initiation and perpetuation of the production of Dsg3-specific auto-Ab by B cells. In PV and BP, autoreactive CD4+ T cells recognize distinct epitopes of the extracellular portions of Dsg3 and BP180 [BP antigen 2 (BPAG2) or type XVII collagen], respectively, and produce preferentially T helper type 2 (TH2) cytokines. Auto-Ab of the TH2-dependent IgG4 subtype are preferentially seen in the active stages of both PV and BP, while auto-Ab of the TH1-dependent IgG1 subclass are predominant during the chronic course of these disorders. These observations suggest that autoreactive TH2 cells may provide targets to specifically modulate the T cell-dependent production of pathogenic auto-Ab in these disorders.

1.
Lever WF: Pemphigus. Medicine (Baltimore) 1953;32:1–123.
2.
Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI: Characterization of bullous pemphigoid antigen: A unique basement membrane protein of stratified epithelia. Cell 1981;24:897–903.
3.
Huilgol SC, Black MM: Management of the immunobullous disorders. II. Pemphigus. Clin Exp Dermatol 1995;20:283–293.
4.
Anhalt GJ, Kim S, Stanley JR: Paraneoplastic pemphigus: An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990;323:1729–1735.
5.
Emery DJ, Diaz LA, Fairly JA, Lopez A, Taylor AF, Giudice GJ: Pemphigus foliaceus and pemphigus vulgaris autoantibodies react with the extracellular domain of desmoglein-1. J Invest Dermatol 1995;104:323–328.
6.
Hashimoto T, Gamou S, Korman NJ, Boorsma DM, Stevens HP, Black MM, Bhogal BS, Chorzelski TP, Watanabe K, Amagai M: Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest Dermatol 1995;104:829–834.
7.
Hertl M: Molecular characterization of autoantibodies in pemphigus; in Conrad K, Humbel RL, Meurer M, Shoenfeld Y, Tan EM (eds): Pathogenic and Diagnostic Relevance of Autoantibodies. Berlin, Pabst, 1998.
8.
Korman NJ, Eyre RW, Zone J, Stanley JR: Drug-induced pemphigus: Autoantibodies directed against the pemphigus antigen complexes are present in penicillamine- and captopril-induced pemphigus. J Invest Dermatol 1991;96:273–276.
9.
Oursler JR, Labib RS, Ariss-Abdo L, Burke T, O’Keefe EJ, Anhalt GJ: Human autoantibodies against desmoplakins in paraneoplastic pemphigus. J Clin Invest 1992;89:1775–1782.
10.
Amagai M, Klaus-Kovtun V, Stanley JR: Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991;67:869–877.
11.
Amagai M, Hashimoto T, Shimizu N, Nishikawa T: Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994;94:59–67.
12.
Bedane C, Prost C, Thomine E, Intrator L, Joly P, Caux F, Blecker M, Bernard P, Leboutet MJ, Tron F, Lauret P, Bonnetblanc JM, Dubertret L: Binding of autoantibodies is not restricted to desmosomes in pemphigus vulgaris: Comparison of 14 cases of pemphigus vulgaris and 10 cases of pemphigus foliaceus studied by Western immunoblot and immunoelectron microscopy. Arch Dermatol Res 1996;288:343–352.
13.
Hashimoto T, Amagai M, Watanabe K, Dmochowski M, Chidgey MAJ, Yue KKM, Garrod DR, Nishikawa T: A case of pemphigus vulgaris showing reactivity with pemphigus antigens (Dsg1 and Dsg3) and desmocollins. J Invest Dermatol 1995;104:541–544.
14.
Joly P, Tron F, Lauret P, Delpech A, Ghohestani R, Zitouni M, Thomine E, Gilbert D: Identification of a new antibody population directed against a desmosomal plaque antigen in pemphigus vulgaris and pemphigus foliaceus. J Invest Dermatol 1997;108:469–475.
15.
Nguyen VT, Ndoye A, Shultz LD, Grando SA: Binding of pemphigus antibodies to the epidermis of mice lacking desmoglein 3. J Invest Dermatol 1998;110:506A.
16.
Wucherpfennig KW, Yu WB, Bhol K, Monos DS, Argyris E, Karr RW, Ahmed AR, Strominger JL: Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: Charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA 1995;92:11935–11939.
17.
Lin MS, Swartz SL, Lopez A, Ding X, Fernandez-Vina MA, Stastny P, Fairley JA, Diaz L: Development and characterization of desmoglein 3-specific T cells from patients with pemphigus vulgaris. J Clin Invest 1997;99:31–40.
18.
Hertl M, Amagai M, Ishii K, Stanley J, Sundaram H, Katz SI: Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. J Invest Dermatol 1998;110:62–66.
19.
Hertl M, Karr RW, Amagai M, Katz SI: Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3-specific T cell responses in pemphigus vulgaris patients and normals. J Invest Dermatol 1998;110:388–392.
20.
Riechers R, Grötzinger A, Hertl M: HLA class II restriction of autoreactive T cell responses in pemphigus vulgaris and potential application for a specific immunotherapy. Autoimmunity 1999;30:183–196.
21.
Lin MS, Fu CF, Aoki V, Hans-Filho G, Rivitti EA, Moraes JR, Moraes ME, Lazaro AM, Giudice GJ, Stastny P, Diaz LA: Desmoglein-1-specific T lymphocytes from patients with endemic pemphigus foliaceus (fogo selvagem). J Clin Invest 2000;105:207–213.
22.
Nishifuji K, Amagai M, Kuwana M, Iwasaki T, Nishukawa T: Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: Requirement of T cell collaboration for autoantibody production. J Invest Dermatol 2000;114:88–94.
23.
Juhasz I, Lazarus GS, Murphy GF, Shih IM, Herlyn M: Development of pemphigus vulgaris-like lesions in severe combined immunodeficiency disease mice reconstituted with lymphocytes from patients. J Clin Invest 1993;92:2401–2407.
24.
Fan JL, Memar O, McCormick DJ, Prabhakar BS: BALB/c mice produce blister-causing antibodies upon immunization with a recombinant human desmoglein 3. J Immunol 1999;163:6228–6235.
25.
Toto P, Feliciani C, Amerio P, Suzuki H, Wang B, Shivji GM, Woodley D, Sauder DN: Immune modulation in pemphigus vulgaris: Role of CD28 and IL-10. J Immunol 2000;164:522–529.
26.
Ahmed AR, Yunis EJ, Khatri K, Wagner R, Notani G, Awdeh Z, Alper CA: Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci USA 1990;87:7658–7662.
27.
Ahmed AR, Wagner R, Khatri K, Notani G, Awdeh Z, Alper CA, Yunis EJ: Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci USA 1991;88:5056–5061.
28.
Ahmed AR, Mohimen A, Yunis EJ, Mirza NM, Kumar V, Beutner EH, Alper CA: Linkage of pemphigus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients. J Exp Med 1993;177:419–424.
29.
Sinha AA, Brautbar C, Szafer F, Friedmann A, Tzfoni E, Todd JA, Steinman L, McDevitt HO: A newly characterized HLA-DQβ allele associated with pemphigus vulgaris. Science 1988;239:1026–1029.
30.
Bhol K, Ahmed AR, Aoki V, Mohimen A, Nagarwalla N, Natarajan K: Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: A model for autoimmunity. Proc Natl Acad Sci USA 1995;92:5239–5243.
31.
Hernandez C, Chan LS, Amagai M: Pemphigus foliaceus: Preferential binding of IgG1 and C3 at the upper epidermis. Br J Dermatol 1997;136:249–252.
32.
Tremeau-Martinage C, Bazex J, Oksman F: Immunoglobulin G subclass distribution of anti-intercellular substance antibodies in pemphigus (in French). Ann Dermatol Venereol 1995;122:409–411.
33.
Anhalt GJ, Labib KS, Vorhees JS, Beals TF, Diaz LA: Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982;306:1189–1192.
34.
Seishima M, Kitajima Y, Hashimoto T, Mori S, Osada K, Esaki C: Pemphigus IgG, but not bullous pemphigoid IgG, causes a transient increase in intracellular calcium and inositol 1,4,5-triphosphate in DJM-1 cells, a squamous cell carcinoma line. J Invest Dermatol 1995;104:33–37.
35.
Esaki C, Kitajima Y, Osada K, Yamada T, Seishima M: Pharmacologic evidence for involvement of phospholipase C in pemphigus IgG-induced inositol 1,4,5-trisphosphate generation, intracellular calcium increase, and plasminogen activator secretion in DJM-1 cells, a squamous cell carcinoma line. J Invest Dermatol 1995;105:329–333.
36.
Kowalczyk AP, Green KJ, Stanley JR, Hashimoto T, Borgwardt JE, Anderson JE: Pemphigus sera recognize conformationally sensitive epitopes in the amino-terminal region of desmoglein-1. J Invest Dermatol 1995;105:147–152.
37.
Shimizu H, Nishikawa T, Hashimoto T, Kikuchi A, Ishiko A, Masunaga T: Pemphigus vulgaris and pemphigus foliaceus sera show an inversely graded binding pattern to extracellular regions of desmosomes in different layers of human epidermis. J Invest Dermatol 1995;105:153–159.
38.
Koch PJ, Mahoney MG, Ishikawa H, Pulkkinen L, Uitto J, Shultz L, Murphy GF, Whitacker-Menezes D, Stanley JR: Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol 1997;137:1091–1102.
39.
Mahoney MG, Wang Z, Rothenberger KL, Koch PJ, Amagai M, Stanley JR: Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999;103:461–468.
40.
Shirakata Y, Hashimoto K, Nishikawa T, Hanakawa Y, Amagai M: Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1. J Invest Dermatol 1998;110:76–78.
41.
Borradori L, Sonnenberg A: Hemidesmosomes: Roles in adhesion, signaling and human diseases. Curr Opin Cell Biol 1996;8:647–656.
42.
Giudice GJ, Emery DJ, Diaz LA: Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 1992;99:243–250.
43.
Borradori L, Koch PJ, Niessen CM, Erkeland S, van Leusden MR, Sonnenberg A: The localization of bullous pemphigoid antigen 180 (BP180) in hemidesmosomes is mediated by its cytoplasmic domain and seems to be regulated by the β4 integrin subunit. J Cell Biol 1997;136:1333–1347.
44.
Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, Guidice GJ: A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993;92:2480–2488.
45.
Büdinger L, Borradori L, Yee C, Eming R, Ferencik R, Grosse-Wilde H, Merk HF, Yancey KB, Hertl M: Identification and characterization of autoreactive CD4+ T cell responses to the extracellular domain of bullous pemphigoid antigen 2 in patients with bullous pemphigoid and normals. J Clin Invest 1998;102:2082–2089.
46.
Zillikens D, Rose PA, Balding SD, Liu Z, Olague-Marchan M, Diaz LA, Giudice GJ: Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 1997;109:573–579.
47.
Lin MS, Giudice GJ, Diaz LA: Analysis of the humoral and cellular immune response of patients with bullous pemphigoid. J Invest Dermatol 1999;112:615A.
48.
Bernard P, Prost C, Aucouturier P, Durepaire N, Denis F, Bonnetblanc JM: The subclass distribution of IgG autoantibodies in cicatricial pemphigoid and epidermolysis bullosa acquisita. J Invest Dermatol 1991;97:259–263.
49.
Delaporte EA, Dubost-Brama R, Ghohestani R, Nicolas JF, Neyrinck JL, Bergoend H, Janin A, Capron M: IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid. J Immunol 1996;157:3642–3647.
50.
Delgado JC, Turbay D, Yunis EJ, Yunis JJ, Morton ED, Bhol K, Norman R, Alper CA, Good RA, Ahmed AR: A common major histocompatibility complex class II allele HLA-DQβ1*0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci USA 1996;93:8569–8571.
51.
Bernard P, Bedane C, Bonnetblanc JM: Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: A cohort analysis of 94 elderly patients. Br J Dermatol 1997;136:694–698.
52.
Haase C, Büdinger L, Borradori L, Yee C, Merk HF, Yancey KB, Hertl M: Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. J Invest Dermatol 1998;110:282–286.
53.
Zillikens D, Mascaro JM, Rose PM, Liu Z, Ewing SM, Caux F, Hoffmann RG, Diaz LA, Giudice GJ: A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997;109:679–683.
54.
Christophoridis S, Büdinger L, Borradori L, Hunzicker T, Merk H, Hertl M: IgG, IgA, and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullosis dermatosis. Br J Dermatol, in press.
55.
Morrison LH, Labib RS, Zone JJ, Diaz LA, Anhalt GJ: Herpes gestationis autoantibodies recognize a 180-kD human epidermal antigen. J Clin Invest 1988;81:2021–2026.
56.
Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Liu Z, Diaz LA: Bullous pemphigoid and herpes gestationis autoantibodies recognize a common noncollagenous site on the BP180 ectodomain. J Immunol 1993;151:5742–5750.
57.
Lin MS, Gharia MA, Swartz SJ, Diaz LA, Giudice GJ: Identification and characterization of epitopes recognized by T lymphocytes and autoantibodies from patients with herpes gestationis. J Immunol 1999;162:4991–4997.
58.
Balding SD, Prost C, Diaz LA, Bernard P, Badane C, Aberdam D, Giudice GJ: Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J Invest Dermatol 1996;106:141–146.
59.
Zone JJ, Taylor TB, Kadunce DP, Meyer LJ: Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. J Clin Invest 1990;85:812–820.
60.
Zone JJ, Taylor TB, Meyer LJ, Petersen MJ: The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BP180. J Invest Dermatol 1998;110:207–210.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.